321 related articles for article (PubMed ID: 33529172)
1. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.
Matsuda K; Migueles SA; Huang J; Bolkhovitinov L; Stuccio S; Griesman T; Pullano AA; Kang BH; Ishida E; Zimmerman M; Kashyap N; Martins KM; Stadlbauer D; Pederson J; Patamawenu A; Wright N; Shofner T; Evans S; Liang CJ; Candia J; Biancotto A; Fantoni G; Poole A; Smith J; Alexander J; Gurwith M; Krammer F; Connors M
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33529172
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
Alexander J; Ward S; Mendy J; Manayani DJ; Farness P; Avanzini JB; Guenther B; Garduno F; Jow L; Snarsky V; Ishioka G; Dong X; Vang L; Newman MJ; Mayall T
PLoS One; 2012; 7(2):e31177. PubMed ID: 22363572
[TBL] [Abstract][Full Text] [Related]
3. Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.
Khurana S; Coyle EM; Manischewitz J; King LR; Ishioka G; Alexander J; Smith J; Gurwith M; Golding H
PLoS One; 2015; 10(1):e0115476. PubMed ID: 25629161
[TBL] [Abstract][Full Text] [Related]
4. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
5. Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.
Matsuda K; Huang J; Zhou T; Sheng Z; Kang BH; Ishida E; Griesman T; Stuccio S; Bolkhovitinov L; Wohlbold TJ; Chromikova V; Cagigi A; Leung K; Andrews S; Cheung CSF; Pullano AA; Plyler J; Soto C; Zhang B; Yang Y; Joyce MG; Tsybovsky Y; Wheatley A; Narpala SR; Guo Y; Darko S; Bailer RT; Poole A; Liang CJ; Smith J; Alexander J; Gurwith M; Migueles SA; Koup RA; Golding H; Khurana S; McDermott AB; Shapiro L; Krammer F; Kwong PD; Connors M
Sci Immunol; 2019 Apr; 4(34):. PubMed ID: 31004012
[TBL] [Abstract][Full Text] [Related]
6. Construction of a recombinant duck enteritis virus (DEV) expressing hemagglutinin of H5N1 avian influenza virus based on an infectious clone of DEV vaccine strain and evaluation of its efficacy in ducks and chickens.
Wang J; Ge A; Xu M; Wang Z; Qiao Y; Gu Y; Liu C; Liu Y; Hou J
Virol J; 2015 Aug; 12():126. PubMed ID: 26263920
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
8. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
Kim EH; Han GY; Nguyen H
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
[TBL] [Abstract][Full Text] [Related]
9. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
[TBL] [Abstract][Full Text] [Related]
10. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
11. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
Front Immunol; 2019; 10():2006. PubMed ID: 31552018
[TBL] [Abstract][Full Text] [Related]
12. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
13. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
14. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
15. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
16. Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier.
Jazayeri SD; Ideris A; Zakaria Z; Yeap SK; Omar AR
Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):417-27. PubMed ID: 22512819
[TBL] [Abstract][Full Text] [Related]
17. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
19. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses.
Wang Z; Gao J; Yu Q; Yang Q
Future Microbiol; 2012 Aug; 7(8):1003-10. PubMed ID: 22913358
[TBL] [Abstract][Full Text] [Related]
20. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge.
Smith D; Streatfield SJ; Acosta H; Ganesan S; Fattom A
Vaccine; 2019 Sep; 37(42):6162-6170. PubMed ID: 31495593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
